
Regulus Therapeutics (RGLS) P/E Ratio
P/E Ratio as of Jul 1, 2025: -11.23
Average-11.19
Median-11.23
Minimum-11.42
Maximum-10.84
-11.23
Past Month-0.32 (2.93%)
The P/E ratio for Regulus Therapeutics (RGLS) is -11.23 as of Jul 1, 2025. This represents a increase of 210.22% compared to its 12-month average P/E ratio of -3.62. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Regulus Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Regulus Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Regulus Therapeutics to industry peers.
Regulus Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Regulus Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Regulus Therapeutics to industry peers.
Regulus Therapeutics (RGLS) P/E Ratio Insights
See Regulus Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Regulus Therapeutics (RGLS)
Order type
Buy in
Order amount
Est. shares
0 shares
Regulus Therapeutics (RGLS) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jul 1, 2025 | $8.16 | -11.23 |
Jun 2, 2025 | $7.94 | -10.92 |
May 1, 2025 | $7.85 | -8.96 |
Apr 1, 2025 | $1.75 | -2.00 |
Mar 3, 2025 | $1.26 | -1.17 |
Feb 3, 2025 | $1.23 | -1.14 |
Jan 2, 2025 | $1.56 | -1.45 |
Regulus Therapeutics (RGLS) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -11.23 | +669.18% |
2024 | -1.46 | +82.50% |
2023 | -0.80 | +25.00% |
2022 | -0.64 | -33.33% |
2021 | -0.96 | -61.13% |
2020 | -2.47 | — |
FAQs About Regulus Therapeutics (RGLS) P/E ratio
The latest P/E ratio of Regulus Therapeutics (RGLS) is -11.23, as of Jul 1, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Regulus Therapeutics’s last 12-month average P/E ratio is -3.62, compared to its current P/E ratio of -11.23. This reflects a increase of 210.22%.
Regulus Therapeutics’s current P/E ratio of -11.23 is higher than its last 12-month average P/E of -3.62. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Regulus Therapeutics’s average P/E ratio over the last 3 years is -1.82. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Regulus Therapeutics’s average P/E ratio over the last 5 years is -1.79. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.